Work

Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.1074

Authors: Holly Tovey, Joel S. Parker, Katherine A. Hoadley, Richard D. Kennedy, Orsolya Sipos, Lucy Kilburn, Sarah Kernaghan, Patrycja Gazinska, Syed Haider, Sarah E Pinder, Judith Bliss, Charles M. Perou, Anita Grigoriadis, Andrew Tutt, Maggie Chon U Cheang, on behalf of the TNT trial management group

Institutions: Institute of Cancer Research, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Almac (United Kingdom), Breast Cancer Now, King's College London

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032522235

Cites:

Cited by:

Related to: 10